Jaguar HealthJAGX -5.55%22 Pretax Margin % is 43.08% as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Jaguar Health ranks worse than 52.39% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Jaguar Health's Pre-Tax Income for the
three
months ended in Mar. 2026 was $8.72 Mil. Jaguar Health's Revenue for the
three
months ended in Mar. 2026 was $20.25 Mil. Therefore, Jaguar Health's pretax margin for the quarter that ended in Mar. 2026 was 43.08%.
The historical rank and industry rank for Jaguar Health's Pretax Margin % or its related term are showing as below:
JAGX'
s Pretax Margin % Range Over the Past 10 Years
Min: -10376.06 Med: -568.13 Max: -117.38
Current: -117.38
JAGX's Pretax Margin % is ranked worse than 52.39% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs JAGX: -117.38
Jaguar Health (NAS:JAGX) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Jaguar Health Pretax Margin % Related Terms
Jaguar Health Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAGX vs MBRX, BCDA, GRTX: Pretax Margin % Comparison
For the Biotechnology subindustry, Jaguar Health's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a Pretax Margin % of 43.08% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #493 out of 941 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Jaguar Health's Pretax Margin % too high?
Jaguar Health's current Pretax Margin % is 43.08%. Based on the distribution chart, Jaguar Health ranks #493 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Pretax Margin % compare to MBRX and BCDA?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #493 out of 941 companies for Pretax Margin %. This places Jaguar Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jaguar Health and its competitors. Jaguar Health's current Pretax Margin % is 43.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current Pretax Margin % of 43.08%. The current Pretax Margin % is 43.08%. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Pretax Margin % is 43.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score
Get the complete analysis for JAGX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
